Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


Hughes Hubbard’s Downie and Voisin advise on Merck acquisition

Hughes Hubbard’s Downie and Voisin advise on Merck acquisition

Nadine Voisin (Left) & Sarah Downie (Right)

The pharmaceutical sector has seen a flurry of big M&A deals lately, and Hughes Hubbard & Reed partners Sarah Downie and Nadine Voisin have served on the team for another multi-billion dollar deal: Merck & Co.’s $3.85 billion purchase of Idenix Pharmaceuticals Inc.

The two companies announced the deal on June 9 after their boards approved the sale, which should close in the third quarter. Merck agreed to pay $24.50 a share for the company, triple Idenix’s closing price of $7.23 on June 6, according to the firm.

Merck plans to combine the two companies’ most promising drugs to produce a faster, more effective cure for hepatitis C. Idenix currently has three hepatitis C drugs in clinical development, and Merck markets three hepatitis C medications: Victrelis, PegIntron and Rebetol.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies,” Dr. Roger Perlmutter, president of Merck Research Laboratories, said in a statement. “Idenix’s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regime that has a duration of treatment as short as possible for millions of patients in need around the world.”

Hughes Hubbard partner James Modlin led the team.

Based in New York, Downie is a partner in the firm’s Employee Benefits & Executive Compensation department. She advises plan sponsors, employers, management and executives on all aspects of compensation and benefits. She has experience with ERISA, the Internal Revenue Code, COBRA, HIPAA and federal health care reform legislation.

Voisin is co-head of the firm’s employment practice group in Paris. She advises French companies and foreign groups located on French territory about individual and collective employment relations. She has specific experience relating to the management of company executives and managers’ careers, both at the French and international level, and more particularly with respect to issues involving remuneration, social protection and negotiating management departures.

Contributing Author

author image

Amy I. Stickel

Amy I. Stickel has extensive experience covering the legal, financial and pharmaceutical industries as a writer and editor. A past managing editor of Corporate Legal Times and...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.